11th week of 2009 patent applcation highlights part 38 |
Patent application number | Title | Published |
20090068089 | Novel method of manufacture of silver oxide nano particles - We disclose a method of manufacture of silver oxide nano metal particles of 2-10 mm size with specific phase and geometry in their exterior and interior making them suitable for use as potent antimicrobial and styptic agents. | 2009-03-12 |
20090068090 | METHODS FOR REACTING AND SEPARATING COMPONENTS OF A GAS-PHASE EQUILIBRIUM REACTION AND A CENTRIFUGAL SEPARATION DEVICE FOR SAME - A method of separating gaseous components. An equilibrium-limited, gas phase reaction is conducted in a centrifugal separation device and at least a portion of a first product of the reaction is separated from a reaction mixture comprising at least one reactant and at least one product in the centrifugal separation device. In another embodiment, the equilibrium-limited, gas phase reaction is conducted in a reactor and a reaction mixture is transferred from the reactor to the centrifugal separation device for separation of at least a portion of the first product. A gas centrifuge comprising at least one rotor and a catalyst is disclosed, as is a gas cyclone comprising the catalyst. The catalyst is formulated to increase a rate of the equilibrium-limited, gas phase reaction. | 2009-03-12 |
20090068091 | EUO-STRUCTURAL TYPE ZEOLITE THAT CONTAINS THE N,N-DIMETHYL-N,N-DI(3,3-DIMETHYLBUTYL)AMMONIUM CATION AND ITS PROCESS FOR PREPARATION - A process for preparing a zeolite beta is described, comprising at least the following steps:
| 2009-03-12 |
20090068092 | Microporous Crystalline Zeolite Material, Zeolite ITQ-32, Preparation Method Thereof and Use of Same - The invention relates to a microporous crystalline zeolite material which, in the calcined state and in the absence of defects in the crystalline lattice thereof, manifested by the presence of silanols, has empirical formula x(M | 2009-03-12 |
20090068093 | BIMETALLIC CATALYST FOR NOX REDUCTION IN ENGINE EXHAUST - A catalyst made by the introduction of copper ions and cobalt ions into a Y-type zeolite to produce a CuCoY zeolite improves the reduction of NOx in exhaust from a lean bum engine, such as a diesel engine. A dual bed selective reduction reactor in the exhaust stream comprising a first bed of BaY or of Ag/alumina and a second bed of CuCoY is particularly effective in reduction of NOx. In one embodiment, the exhaust stream is suitably treated with an oxidant, such as ozone, and a reductant, such as a diesel hydrocarbon or oxygenated diesel hydrocarbon, before the exhaust passes in contact with the dual bed catalyst. | 2009-03-12 |
20090068094 | INHIBITORS OF ENDO-EXONUCLEASE ACTIVITY FOR TREATING CANCER - The present invention relates to the treatment of cancer with compounds that inhibit the activity of endo-exonuclease. Endo-exonuclease has been shown to be necessary for the repair of damaged DNA. Compounds that inhibit the activity of endo-exonuclease have been shown to be particularly effective for treating cancer when used in combination with drugs that induce DNA breaks such as cisplatin and mitomycin C. These compounds have a synergistic effect when used in combination for inhibiting tumour growth. The invention includes pharmaceutical compositions for inhibiting tumour growth comprising a compound that inhibits endo-exonuclease activity. These pharmaceutical compositions preferably include compounds that induce DNA breaks. The invention includes methods of treating cancer with these pharmaceutical compositions and uses of these compositions to treat cancer. The preferred compounds that inhibit the activity of endo-exonuclease have low toxicity. One such compound is pentamidine. The invention also includes a method for diagnosing cancer and monitoring its progression. This aspect of the invention involves isolating serum from a patient; measuring the concentration of endo-exonuclease in said serum and determining whether said concentration is above a predetermined mean. | 2009-03-12 |
20090068095 | CARBONIC ANHYDRASE IX (G250) ANITBODIES AND METHODS OF USE THEREOF - The invention provides scFv antibodies and monoclonal antibodies that bind to and decrease an activity of Carbonic Anhydrase IX (G250). Also provided are methods of treating and/or preventing cancer, such as renal clear cell cancer. Also provided are methods of identifying a carbonic anhydrase IX (G250) protein. The invention additionally provides methods of modifying immune effector cells, and the immune effector cells modified thereby. | 2009-03-12 |
20090068096 | SEQUENCE OF STRO-1 ANTIBODY VARIABLE REGION - The amino acid sequence of the heavy chain polypeptide and the light chain polypeptide of the STRO-1 antibody is disclosed. Also disclosed are methods for detecting and isolating cells expressing the STRO-1 cell surface protein. | 2009-03-12 |
20090068097 | METHOD FOR NON-INVASIVE DETECTION AND TREATMENT OF CEREBRAL ANEURYSMS - Described herein is a method for non-invasive detection and treatment of intra-cranial aneurysms. Antibodies are provided to specifically react/bind with antigens of the cerebral aneurism wall. The antibodies may be bound to a label and/or to a therapeutic agent for diagnosis and/or for treatment purposes thereof. Intra-cranial aneurysms are thus non-invasively detected before rupture occurs and are specifically treated. | 2009-03-12 |
20090068098 | ANTIBODIES AND RELATED MOLECULES THAT BIND TO 58P1D12 PROTEINS - Antibodies and molecules derived therefrom that bind to 58P1D12 protein and variants thereof, are described wherein 58P1D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 58P1D12 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 58P1D12 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 58P1D12 can be used in active or passive immunization. | 2009-03-12 |
20090068099 | CANCEROUS DISEASE MODIFYING ANTIBODIES - The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells. | 2009-03-12 |
20090068100 | CANCEROUS DISEASE MODIFYING ANTIBODIES - The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells. | 2009-03-12 |
20090068101 | A1 Adenosine Receptor Antagonists - This invention relates to compounds of formula (I): wherein R | 2009-03-12 |
20090068102 | TREATING STROKE - Methods of treating stroke with blocking agents of TWEAK or TWEAK receptor are presented. | 2009-03-12 |
20090068103 | APTAMERS LABELED WITH 68GA - This invention relates to novel nucleotide-based compounds, methods of making radiolabeled compounds and use of such compounds for diagnostic imaging. Provided are compounds according to Formula (I) A-B-L-C, wherein A stands for an aptamer, B is absent or stands for a bridging structure, L is a linker, and C is a metal ion chelator. All substituents are defined in detail in the description. Preferred embodiments of said compounds bind to Tenascin-C. | 2009-03-12 |
20090068104 | Substantially Homogeneous Bio-Affecting Material Having a Pre-Determined Ratio of Bioaffecting Component to Cell Targeting Component, the Method for Making Such a Material and the Method of its use - A homogeneous conjugate for targeting and treating diseased cells wherein the conjugate has a predetermined ratio of drug molecules to protein molecules that preferentially bind to such cells and a method for making such a conjugate. The method of making the conjugate comprises adding drug molecules to linker molecules in a manner that effectively results in one molecule of drug for each molecule of linker followed by the addition of the drug-linker combination to protein molecules in order to achieve the predetermined ratio of drug molecules to protein molecules. | 2009-03-12 |
20090068105 | ISATIN ANALOGUES AND USES THEREFOR - Novel isatin analogues, including isatin analogues comprising Michael Acceptors (IMAs) are disclosed. Further disclosed are methods of synthesis of the isatin analogues, and uses of the analogues, including inhibition of caspase-3 and caspase-7, and in vivo imaging of apoptosis by Positron emission tomography (PET) or Single Photon Emission Computed Tomography (SPECT). | 2009-03-12 |
20090068106 | Conjugation Product - A peptide which selectively inhibits α | 2009-03-12 |
20090068107 | ENZYME REGULATING ETHER LIPID SIGNALING PATHWAYS - A multidimensional profiling strategy that combines activity-based proteomics and metabolomics was used to determine that an active protein, which is a previously uncharacterized enzyme highly elevated in aggressive cancer cells, serves as a central node in an ether lipid signaling network that bridges platelet-activating factor and the lysophospholipids. Biochemical studies confirmed that the active protein regulates this pathway by hydrolyzing the metabolic intermediate 2-acetyl monoalkylglycerol. Inactivation of the active protein disrupted ether lipid metabolism in cancer cells and impaired cell migration and tumor growth in vivo. | 2009-03-12 |
20090068108 | BIOSPECIFIC CONTRAST AGENTS - Methods and apparatuses for detecting a condition of a sample (including cervical cancers and pre-cancers) through reflectance and/or fluorescence imaging. A sample is obtained. One or more metallic nanoparticles and/or one or more quantum dots are obtained. The one or more metallic nanoparticles and/or one or more quantum dots are coupled to one or more biomarkers of the sample that are associated with the condition. A reflectance and/or fluorescence image of the sample is then taken. The image(s) exhibit characteristic optical scattering from the one or more metallic nanoparticles and/or characteristic fluorescence excitation from the one or more quantum dots to signal the presence of the one or more biomarkers. In this way, the condition can be readily screened or diagnosed. | 2009-03-12 |
20090068109 | ANTI-MCP-1 ANTIBODIES, COMPOSITIONS, METHODS AND USES - The present invention relates to at least one novel anti-MCP-1 antibody, including isolated nucleic acids that encode at least one anti-MCP-1 antibody, MCP-1, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices. | 2009-03-12 |
20090068110 | ANTIBODIES TO INSULIN-LIKE GROWTH FACTOR RECEPTOR - The invention provides various antibodies that bind to insulin-like growth factor-I receptor (IGF-1R), methods for making such antibodies, compositions and articles incorporating such antibodies, and their uses in treating, for example, cancer or aging. The antibodies include murine, chimeric, and humanized antibodies. | 2009-03-12 |
20090068111 | METHODS OF IDENTIFYING LEAD COMPOUNDS THAT MODULATE TOXICITY OF NEUROTOXIC POLYPEPTIDES - Methods of screening candidate agents to identify lead compounds for the development of therapeutic agents for the treatment of a neurodegenerative disease, such as Huntington's Disease and Parkinson's Disease and methods for identifying a mutation in, or changes in expression of, a gene associated with neurodegenerative disease, such as Huntington's Disease and Parkinson's Disease, are provided. | 2009-03-12 |
20090068112 | Magnetic Nanoparticles for Imaging - A medical imaging system that enables the discovery of malignant tissue utilizing contrast agents and heating agents made of magnetic nanoparticles that are delivered to tumor sites utilizing attenuated strains of bacteria that seek and reside at tumor sites is disclosed. The thermal contrast agents may be temperature self-controlled magnetic nanoparticles that may be encapsulated in a biocompatible coating. The thermal contrast agents may be uploaded into attenuated strains of bacteria that seek and reside in tumor tissue when placed into a bloodstream of a patient. An alternating magnetic field device with a prescribed frequency range may be used to induce heating of the magnetic nanoparticles in the patient, and a thermal scan may be utilized to identify tumors. In another embodiment, the contrast agent may be formed from magnetic nanoparticles having distinct magnetic moment profiles, and a MRI system may be utilized to identify tumors with such contrast agent. | 2009-03-12 |
20090068113 | AMPHIPHILIC SQUARAINE DYES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF - The present invention relates to amphiphilic squaraine dyes of the general formula (1) as shown below Formula (1) wherein, R | 2009-03-12 |
20090068114 | Noninvasive Thermometry Monitoring System - A noninvasive thermometry monitoring system for determining a temperature of tissue to which hyperthermia treatment is administered is disclosed. The monitoring system may incorporate magnetic nanoparticles having known moments such that once exposed to an alternating magnetic field, the magnetic nanoparticles increase in temperature. Imaging systems can disclose the magnetic nanoparticles within a patient. The temperature of the magnetic nanoparticles can be determined by comparing the magnetic nanoparticle with known temperatures for that type of magnetic nanoparticle. The image of the magnetic nanoparticles may be compared with surrounding tissue to determine the temperature of the surrounding tissue that is exposed to hyperthermia treatment. | 2009-03-12 |
20090068115 | Amine Functionalized Superparamagnetic Nanoparticles for the Synthesis of Bioconjugates and Uses Therefor - Amine functionalized magnetic nanoparticle compositions and processes for synthesizing the same are described. The process consists of obtaining a carboxylated polymer in substantially pure form, which is used to prepare a substantially size homogeneous, polymer coated carboxyl, functionalized magnetic nanoparticle. The carboxyl groups are converted to reactive primary amino groups by the use of a water-soluble carbodiimide followed by reaction of a large excess of a diamine. The amine-terminated nanoparticles are then reacted with bifunctional crosslinking agents and with various biomolecules to make nanoparticles for in vitro assays, cell sorting applications and target specific MR contrast agents. | 2009-03-12 |
20090068116 | Chemical system with self-timing indicator - A luminescent composition, with a luminescent marker and a ionizing agent exhibiting luminescence for an indicatory period once intermixed, and with luminance intensity remaining at a threshold intensity during indicatory period. Luminescence also can be exhibited responsive to responsive to excitatory light applied to the composition. The luminescent marker includes a coumarinic compound and the ionizing agent includes an ammonium base. Antimicrobial agents are included. A luminescence measuring apparatus includes a photoemitter and a photodetector responsive to an emissive light induced by photoemitter. An optical filter can be used with the photodetector. A two-phase composition dispensing apparatus includes a first phase reservoir, a second phase reservoir, a mixing nozzle, and a dispensing mechanism. | 2009-03-12 |
20090068117 | STAY-ON SELENIUM FOAM - Provided, among other things, is a delivery module for a non-greasy, non-irritating selenium sulfide composition comprising: (A) an aerosol delivery device; (B) within the aerosol delivery device, the selenium sulfide composition comprising an effective amount of selenium sulfide that is 1% or more by weight of the composition, and a frothing agent, wherein the selenium sulfide composition has a viscosity low enough to support aerosol delivery and the selenium sulfide composition is effective to form a foam upon propellant-driven aerosol delivery; and (C) within the aerosol delivery device, a propellant. | 2009-03-12 |
20090068118 | DEVICE FOR DELIVERY OF A FOAMABLE COMPOSITION - A device for delivery of a foamable composition to a body cavity includes a pressurized composition reservoir; a hollow body having a longitudinally extending wall and having at least one aperture provided through a wall of said body, the proximal end in fluid communication with the reservoir for receiving a foamable composition from said composition reservoir; and an actuator operatively connected to the composition reservoir for effecting release of a foamable composition from said composition reservoir into a body cavity through said hollow body; wherein said body has a length less than about 125 mm and internal diameter in the range of about 1.5 mm to about 3.5 mm, wherein said length and internal diameter are selected to provide a delivery of at least about 70% of the foamable composition during operation. The foam delivery device can have multiple apertures. | 2009-03-12 |
20090068119 | Sprayable Depilatory Composition and a Method of use - A sprayable depilatory composition including a depilatory agent; a surfactant present in the range 0.1% to 5.0% by weight of the composition, wherein the composition has an initial viscosity substantially less than about 7.00 Pas. | 2009-03-12 |
20090068120 | AMIDE COMPOUND OR SALT THEREOF, AND BIOFILM INHIBITOR, BIOFILM REMOVER AND DISINFECTANT CONTAINING THE SAME - The present invention provides a new amide compound and salt thereof that is capable of inhibiting biofilm formation or removing deposited biofilms. The present invention also provides a biofilm formation inhibitor or a biofilm remover containing the amide compound or salt thereof as an active ingredient. | 2009-03-12 |
20090068121 | LANTIBIOTICS AND USES THEREOF - The present invention provides isolated lantibiotics that inhibit Gram negative and Gram positive microbes. The lantibiotic includes an amino acid sequence, wherein the amino acid sequence of the compound and the amino acid sequence of SEQ ID NO:21 or SEQ ID NO:22 have at least 80% identity. The lantibiotics have the characteristic of inhibiting growth of a Gram negative microbe in conditions that do not damage the outer membrane of the Gram negative microbe. The present invention also provides methods for making and using the lantibiotics. | 2009-03-12 |
20090068122 | Dentifrice Compositions for Treating Xerostomia - This invention encompasses an oral composition for treating or preventing dry mouth with following benefits: antibacterial/anti-fungal efficacy, low irritancy, and moisture retention. The compositions can be a toothpaste, a mouth rinse or a spray and include one or more non-ionic surfactants, as foaming agents, one or more broad spectrum anti-microbial ingredient, such as chlorhexidine and cetylpyridinium chloride, and one or more oral surface adhesive polysaccharides that can encage cationic actives to help the deposition and retention of the agents onto oral surfaces and thus provide antimicrobial efficacy. | 2009-03-12 |
20090068123 | FLUORINE ION-RELEASABLE COMPOSITION FOR DENTAL PURPOSES - The invention provides a fluoride ion releasing dental composition including an inorganic powder (a); a fluoride ion releasing material (b); a monomer (c); and a polymerization initiator (d), in which the inorganic powder (a) is made of composite particles in which a layer of polysiloxane is formed on surfaces of substrate particles made of an inorganic material, and the fluoride ion releasing material (b) is at least one fluoride ion releasing material selected from the group consisting of ammonium fluoride, ammonium hydrogen fluoride, a metal fluoride, a polymer including, as a constitutional unit, a vinyl monomer having an acid fluoride group and a fluorine-containing phosphazene monomer. | 2009-03-12 |
20090068124 | NOVEL HETEROCYCLIC SUBSTITUTED CONDENSATION POLYMERS - The invention relates to novel optionally quaternized or protonated condensation polymers having at least one heterocyclic end-group connected to the polymer backbone through a unit derived from an alkylamide, the connection comprising an optionally substituted ethylene group and to the use thereof in body care products and household products. | 2009-03-12 |
20090068125 | TREATMENT FOR MUCOSITIS - This invention relates to a medicament for protecting human mucosal cells from chemotherapy or radiotherapy induced cell death using formulations comprising adenosine or adenosine analogues as a reversible inhibitor of epithelial cell proliferation. The invention also relates to formulations containing adenosine for the prevention of or reduction in mucositis symptoms. | 2009-03-12 |
20090068126 | Composition for surface photoprotection - The molecules capable of absorbing ultraviolet radiation from the cashew nut shell liquid changes are the object of the present invention; it is also described the compositions responsible for protecting the surfaces and chemical processes for the referred molecules production. | 2009-03-12 |
20090068127 | Novel Polysiloxane Sunscreens - The present invention relates to novel sunscreens on the basis of polysiloxanes, to their preparation and to their use, especially in formulations for the protection against harmful effects of sunlight. | 2009-03-12 |
20090068128 | SCAR AND ROSACEA AND OTHER SKIN CARE TREATMENT COMPOSITION AND METHOD - The present invention relates generally to composition and methods for topical application to skin. More particularly, it relates to treatment of scars and rosacea, and other aspects of skin care. A composition is disclosed having a skin toner for cleansing a skin surface, removing dead skin cells, restoring alkali balance, and shrinking skin pores; and a skin moisturizer for increasing water content in the external layers of the skin. | 2009-03-12 |
20090068129 | Aminophenylbenzothiazole compounds - The Use, as a UV filter, of a compound of formula | 2009-03-12 |
20090068130 | SUNLESS TANNING COMPOSITION WITH PHOTOSTABLIZED SUNSCREEN - In one aspect, a cosmetic composition includes a sunless tanning agent and a sunscreen agent. A photostabilizer is added to stabilize the sunscreen agent from the destabilizing effect of the sunless tanning agent. In this manner, UV protection is provided to the user when the cosmetic composition is applied to skin. In another aspect, a water-based sunless tanning/sunscreen composition includes a sunless tanning agent, a sunscreen agent, and a photostabilizer. The sunless tanning agent is DHA, and the sunscreen is avobenzone. Because the avobenzone degrades when exposed to UV radiation when used with DHA, the photostabilizer is added to enable the avobenzone to retain most of its original ability to absorb the UV radiation. The photostabilizer is a low molecular weight copolymer of adipic acid and neopentyl glycol. | 2009-03-12 |
20090068131 | Water-based nail-polish composition - The water-based nail-polish composition includes a mixture of at least one water-based suspension (A) of hard nanoparticles of an acrylic polymer at a glass transition temperature that is greater than or equal to 55° C., in combination with at least one coalescent and/or plasticizing solvent of the polymer; and at least one water-based suspension (B) of nanoparticles of acrylic monomers, partially cross-linked, that have a film formation temperature of less than 15° C. The water-based composition can also contain a solution (C) of an acrylic polymer of low molecular weight that is less than approximately 20,000, with a high acid value, neutralized to a pH of between 7 and 8.5, approximately. | 2009-03-12 |
20090068132 | Resveratrol Ferulate Compounds, Compositions Containing The Compounds, And Methods Of Using The Same - The present invention relates to cosmetic compositions containing resveratrol ferulate in a topically acceptable carrier. Such compositions are particularly effective for skin lightening and anti-aging applications and have excellent color stability and extended shelf life. | 2009-03-12 |
20090068133 | Composition containing a liquid fatty phase gelled with a semi-crystalline copolymer - The invention relates to a semi-crystalline copolymer of organic structure with a melting point of greater than or equal to 30° C. obtained from at least two monomers A and B, A being a lipophilic monomer bearing crystallizable side chain(s) and B being an amorphous lipophilic monomer that is copolymerizable with A, characterized in that the units derived from the monomers A represent less than 50% by weight of the said copolymer. The invention also relates to cosmetic compositions comprising such a copolymer. This composition is in particular in the form of a soft paste that gives a glossy film on keratin materials, especially the lips. | 2009-03-12 |
20090068134 | HAIR COSMETIC - The present invention provides hair cosmetics containing (a) an amideamine (I): | 2009-03-12 |
20090068135 | Durable Fiber Treatment Composition - A fiber treatment composition is presented comprising organomodified silicones having defined physico-chemical properties and a additive which allows the organomodified silicone to be retained on the hair over longer periods of time than traditionally has been the case. The present composition finds particular application on hair that has been damaged through chemical treatments, such as occurs during permanent dyeing, bleaching and permanent waving. | 2009-03-12 |
20090068136 | HAIR CARE COMPOSITIONS - The invention relates to hair care compositions comprising an effective amount of a condensation polymer having at least one, optionally quarternized or protonated, dialkylamide end-group connected through the polymer backbone to a unit derived from an alkylamide, the connection comprising at least one ester linkage. | 2009-03-12 |
20090068137 | ORGANOLEPTIC COMPOUNDS AND THEIR USE IN PERFUME COMPOSITIONS - The present invention is directed to novel compounds which possess unique organoleptic properties containing the following general formula: | 2009-03-12 |
20090068138 | Polyglycerol anti-microbial agents and compositions - Polyglycerol anti-microbial agents and compositions are provided. The agents are effective against a variety of pathogens including fungi, Gram positive bacteria and Gram negative bacteria yet are expected to have low human toxicity due in part to their polymeric nature. Applications for the polyglycerol anti-microbial agents and compositions include those involving human and plant contact, such as cosmetics, hair care products, textiles and plant protections, as well as in applications with much less human contact, such as plastics, coatings, wood, paper and other materials of construction. | 2009-03-12 |
20090068139 | LOOP PEPTIDE AND TGF alpha FOR STIMULATING STEM CELL PROLIFERATION AND MIGRATION - There is disclosed a novel genus of small peptides, smaller than human TGFα, identified as having TGFα biological activity and therefore being useful as pharmacologic agents. It is further disclosed that both TGFα and the genus of small peptides disclosed herein have therapeutic activity to stimulate hematopoiesis, e.g., in patients undergoing cytotoxic cancer chemotherapy, and also act as cytoprotective agents to protect patients undergoing cancer cytotoxic therapy from gastrointestinal (GI) side effects, such as mucositis, and otherwise to support the barrier function of the GI tract, such as when it is harmed by cytotoxic therapy. | 2009-03-12 |
20090068140 | HEPATITIS C VIRUS INHIBITORS - The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection. | 2009-03-12 |
20090068141 | AUTOLOGOUS NATURAL KILLER CELLS AND LYMPHODEPLETING CHEMOTHERAPY FOR THE TREATMENT OF CANCER - The invention provides a simple, cost-effective method of preparing a composition comprising natural killer (NK) cells useful for administering to a human. The method comprises (i) depleting CD3 | 2009-03-12 |
20090068142 | COMPOSITIONS AND METHODS FOR TREATING CORONAVIRUS INFECTION AND SARS - The present invention provides methods of treating a coronavirus infection, and methods of reducing viral load, or reducing the time to viral clearance, or reducing morbidity or mortality in the clinical outcomes, in patients suffering from a coronavirus infection. The present invention further provides methods of reducing the risk that an individual will develop a pathological coronavirus infection, that has clinical sequelae. The present invention further provides methods of reducing the risk that an individual will develop SARS. The present invention further provides methods of treating SARS. The methods generally involve administering a therapeutically effective amount of a Type I or Type III interferon receptor agonist and/or a Type II interferon receptor agonist for the treatment of a coronavirus infection. | 2009-03-12 |
20090068143 | ORALLY EFFECTIVE CANNABINOID ANALOGS - The present invention relates to orally effective ligands of the peripheral cannabinoid receptor CB | 2009-03-12 |
20090068144 | TETRAHYDRO-ISOQUINOLIN-1-ONES FOR THE TREATMENT OF CANCER - The present invention provides a compound selected from compounds of formula I as ligand binding to the HDM2 protein, inducing apoptosis and inhibiting proliferation, and having therapeutic utility in cancer therapy. Compounds of formula (I) can be used as therapeutics for treating stroke, myocardial infarction, ischemia, multi-organ failure, spinal cord injury, Alzheimer's Disease, injury from ischemic events, heart valvular degenerative disease Moreover, compounds of formula (I) can be used to decrease the side effects from cytotoxic cancer agents and to treat viral infections. | 2009-03-12 |
20090068145 | Methods and Compositions Relating to Islet Cell Neogenesis - The present invention provides methods and kits for treating diseases and conditions associated with impaired pancreatic function. The present invention further provides methods of stimulating islet cell neogenesis and stimulating islet cell differentiation from progenitor cells. | 2009-03-12 |
20090068146 | DIARYL UREAS AND COMBINATIONS - The present invention provides methods for treating cancer in humans and other mammals comprising administering a chemotherapeutic agent, such as an interferon, and an aryl urea compound of Formula (I): | 2009-03-12 |
20090068147 | RAAV VECTOR-BASED PRO-OPIOMELANOCORTIN COMPOSITIONS AND METHODS OF USE - Disclosed are methods for the use of pro-opiomelanocortin-encoding polynucleotides in the creation of transformed host cells and transgenic animals. In particular, the use of recombinant adeno-associated viral (rAAV) vector compositions, virions, and pluralities of virus particles that comprise a nucleic acid segment that expresses one or more mammalian pro-opiomelanocortin polypeptides in suitably transformed host cells is described. Also disclosed are methods for the treatment and amelioration of symptoms of a variety of conditions and disorders in an animal, including hyperinsulinemia, obesity, adiposity, overeating, and related eating disorders. | 2009-03-12 |
20090068148 | PEPTIDES OF CAV2.2 THAT INHIBIT PAIN - The present invention relates to peptides of CaV2.2 and their use in the treatment of pain. The sequence of the peptides is derived from the C-terminus of CaV2.2. and is believed to inhibit the interaction of CaV2.2 with Mint1-PDZ1. The invention is related to use of this peptide to treat pain and to use of this peptide in binding reaction with int-PDZ to screen for small molecules that can inhibit pain. | 2009-03-12 |
20090068149 | Use of a Fermented Milk Containing L. Casei for the Manufacture of a Composition for the Prevention or Treatment of a Delayed-Type Hypersensitivity Reaction - The present invention relates to the field of probiotics. More particularly, the invention pertains to the use of a particular strain, | 2009-03-12 |
20090068150 | LACTIC ACID BACTERIA CULTURE OF MUNG BEAN AND THE PREPARATION METHOD OF THE SAME, AND THE COSMETIC COMPOSITION COMPRISING THE SAME - Disclosed is a lactic acid bacteria culture of mung bean obtained by culturing lactic acid bacteria in a culture medium containing mung bean extract. The culture contains the mung bean extract and GABA (ϝ | 2009-03-12 |
20090068151 | Methods and reagents for the enhancement of virus transduction in the bladder epithelium - Agents and methods for enhancing recombinant virus transduction in the bladder epithelium are described. A first method involves contacting the luminal surface of the bladder with a composition comprising a transduction enhancing agent and an oncolytic virus. Alternatively, the luminal surface of the bladder can be contacted first with a pretreatment composition comprising a transduction enhancing agent and, subsequently, with a composition comprising an oncolytic virus. Bladder treatment compositions comprising a transduction enhancing agent and an oncolytic virus are also described. | 2009-03-12 |
20090068152 | GENE TRANSFER FOR REGULATING SMOOTH MUSCLE TONE - The invention provides methods of regulating smooth muscle tone in a subject, comprising the introduction, into smooth muscle cells of the subject, of a DNA sequence encoding a potassium channel protein involved in the regulation of smooth muscle tone, and expression of the DNA sequence in a sufficient number of smooth muscle cells of the subject to regulate smooth muscle tone in the subject. The invention provides methods of gene transfer for treating erectile dysfunction, bladder dysfunction, and other smooth muscle disorders. | 2009-03-12 |
20090068153 | CELL COMPOSITION FOR TISSUE REGENERATION - A method of extracting human progenitor cells from perivascular tissue of human umbilical cord. The extracted cells are then co-cultured with hematopoetic stem cells and are useful to grow and repair human tissues including bone. Also included are related methods and compositions related thereto. | 2009-03-12 |
20090068154 | Cell Composition for Transplant - The present invention provides a cell composition for transplant comprising fibroblasts originating in buccal fat pad. | 2009-03-12 |
20090068155 | METHODS, PHARMACEUTICAL COMPOSITIONS AND ARTICLES OF MANUFACTURE FOR ADMINISTERING THERAPEUTIC CELLS TO THE ANIMAL CENTRAL NERVOUS SYSTEM - Methods and compositions for preventing and treating the damaged and/or degenerating CNS experiencing loss or death of CNS cells. Various embodiments of the invention transport a therapeutically effective amount of, inter alia, at least one therapeutic cell to the CNS by intranasal application to the upper-third of the nasal cavity, thereby bypassing the blood-brain barrier. A pharmaceutical composition according to the invention may comprise at least one therapeutic cell, at least one delivery-enhancement agent, at least one antibiotic, at least one regulatory factor and/or at least one immunosuppressive agent, wherein the composition is delivered to the upper-third of the nasal cavity. The therapeutic cells, once delivered to the CNS, migrate preferentially to the area of damage or degeneration or injury. | 2009-03-12 |
20090068156 | TREATMENT OF MUSCULAR DYSTROPHY WITH CORD BLOOD CELLS - The invention features methods for treating a patient suffering from muscular dystrophy by administration of umbilical cord blood cells, e.g., by IV infusion. | 2009-03-12 |
20090068157 | Derivation of unlimited quantities of neutrophils on monocyte/dendritic cells - A method to generate unlimited numbers of macrophage/dendritic cells or neutrophils from mice, using conditional Hox oncoproteins is disclosed. The invention further includes the establishment of a system to investigate immune responses to microorganisms or diseases involving chronic inflammation. | 2009-03-12 |
20090068158 | THYMIDYLATE KINASE MUTANTS AND USES THEREOF - The invention relates to a composition comprising: a stably integrating delivery vector; a modified mammalian thymidylate kinase (tmpk) wherein the modified mammalian tmpk increases phosphorylation of a prodrug relative to phosphorylation of the prodrug by wild-type human tmpk. The invention also relates to use of these compositions in methods of treatment of diseaseuuius such as graft versus host disease and cancer. | 2009-03-12 |
20090068159 | Insecticidal Compositions and Methods for Making Insect-Resistant Transgenic Plants - The present invention provides isolated polynucleotide sequences encoding ET37, TIC810 and TIC812 proteins from | 2009-03-12 |
20090068160 | USE OF A LYSATE OF BIFIDOBACTERIUM SPECIES FOR TREATING SENSITIVE SKIN - Cosmetic use of an effective amount of at least one lysate of at least one microorganism of the genus | 2009-03-12 |
20090068161 | USE OF A COMBINATION OF HESPERIDIN AND OF A MICROORGANISM FOR INFLUENCING THE BARRIER FUNCTION OF THE SKIN - The cosmetic use of at least an effective amount of hesperidin or of one of its derivatives in combination with at least an effective amount of at least one microorganism, in particular probiotic microorganism, or one of its fractions as agent for preventing a reduction in and/or for reinforcing the barrier function of the skin. | 2009-03-12 |
20090068162 | Stationary Phase Antibody Arrays for Trace Protein Analysis - The present invention relates to the identification of trace proteins and biomarkers, e.g., TH-1/TH-2, cytokines, MMPs and angiogenic modulators in tear fluids. The present invention provides an antibody-based stationary phase array assay for simultaneously identifying, detecting and characterizing the distribution of a wide range of bioactive trace proteins in a tear fluid sample. A method for simultaneously identifying trace proteins in a biological fluid sample using a highly sensitive antibody-array assay is provided. The present invention also provides methods and kits for treating, preventing, and diagnosing ocular diseases, disorders or pathological conditions. | 2009-03-12 |
20090068163 | Transgenic expression cartridges for expressing nucleic acids in the flower tissue of plants - The invention relates to methods for the targeted transgenic expression of nucleic acid sequences in tissues of plants, and to transgenic expression cassettes and expression vectors comprising promoters with expression specificity for floral tissues. The invention further relates to organisms (preferably plants) transformed with these transgenic expression cassettes or expression vectors, to cultures, parts or propagation material derived from these organisms, and to their use for the production of foodstuffs, feedstuffs, seed, pharmaceuticals or fine chemicals. | 2009-03-12 |
20090068164 | SEQUENCE ENABLED REASSEMBLY (SEER) - A NOVEL METHOD FOR VISUALIZING SPECIFIC DNA SEQUENCES - The present invention provides a nucleotide sequence detection system in which a reporter enzyme is split into two halves each half of which is associated with at least one zinc finger domain. Upon DNA binding to the specific sequence defined by the zinc finger domains associated with the respective halves, the split-protein reassembles to reconstitute a functional enzyme. As such, the present invention provides methods of using the nucleotide sequence detection system for various diagnostic and identification purposes. | 2009-03-12 |
20090068165 | Uniformly Conjugated Serine Hydrolases - An organophosphate scavenger is provided, with extended residence time in the mammalian circulation, which can be used in preventive and therapeutic treatment of organophosphate poisoning. The scavenger is a uniformly pegylated serine hydrolase, in which a part of lysine residues were replaced with other residues by site-directed mutagenesis. One part of lysine residues in the hydrolase amino acid sequence is selected for the PEG-coupling, and the other part for the replacement, wherein the selection should ensure that the hydrolase surface shows at least one free amino acid for PEG coupling for all possible views obtained by rotating a 3-D model generated for the hydrolase. | 2009-03-12 |
20090068166 | METHOD AND COMPOSITION FOR PROTECTION AGAINST RADIATION - Methods are described for using an arginine depleting agent such as arginase and derivatives thereof, which reduce physiological arginine levels, as radioprotectants to protect normal mammalian cells from DNA damage caused by ionizing radiation. Treatment can result in the protection of normal tissues in cancer patients undergoing radiotherapy and in protection from the hazardous effects of exposure to radiological dispersal devices or occupational and environmental ionizing radiation. | 2009-03-12 |
20090068167 | COMPOSITIONS FOR PROMOTING WOUND HEALING AND TREATING PSORIASIS - The present invention relates to compositions and methods for promoting healing of cutaneous, mucosal and/or mucocutaneous lesions associated with the presence of a mycoplasma and one or more non-mycoplasma microorganisms. The compositions and methods of the invention also relate to the reduction of joint pain, column pain, and/or skeletal muscle pain | 2009-03-12 |
20090068168 | SUBSTITUTED AMINO ALCOHOLS - Disclosed herein are substituted amino alcohol anti-mycobacterial agents and/or chelation therapy agents of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof. | 2009-03-12 |
20090068169 | 2,4,6-triamino-s-triazine-based compounds which bind to the tail (fc) portion of immunoglobulins and their use - The present invention describes new compounds which are useful for binding to the tail or Fc portion of immunoglobulins and so have utility in those applications which require the non-covalent binding interaction of a molecule with the Fc portion of immunoglobulins. Such applications include the detection and purification of immunoglobulins as well as the treatment of certain autoimmune diseases. | 2009-03-12 |
20090068170 | DROPLET-BASED SELECTION - The present invention generally relates to fluidic droplets, and techniques for screening or sorting such fluidic droplets. In some embodiments, the fluidic droplets may contain cells (e.g., hybridoma cells) that can secrete various species, such as antibodies, for example. In one aspect, a plurality of fluidic droplets containing cells is screened to determine proteins, antibodies, polypeptides, peptides, nucleic acids, or the like. For example, cells able to secrete species such as antibodies may be selected according to certain embodiments of the invention. Examples of such cells include, for instance, immortal cells such as hybridomas, or non-immortal cells such as B-cells. For instance, blood cells may be encapsulated within a plurality of fluidic droplets, and the cells able to produce antibodies may be determined. In some cases, expression or secretion levels may be determined using signaling entities, for example, determinable microparticles present within the fluidic droplet. Other aspects of the invention relate to kits involving such fluidic droplets, methods of promoting the making or use of such fluidic droplets, and the like. | 2009-03-12 |
20090068171 | Protein markers for the detection of thyroid cancer metastasis - This invention relates, e.g., to a method for detecting the presence of lymph node metastases in a subject having papillary thyroid carcinoma (PTC), comprising measuring in a sample from the subject the amount of expression (e.g., the amount of protein, or the amount of mRNA encoding the protein) of one or more of the following proteins: (a) LIMD2, and/or (b) PTPRC, and/or (c) LTB, and/or (d) CD48, and/or (e) ABCC3, wherein a significant amount of over-expression of one or more of protein(s) (a)-(e), compared to the baseline value, indicates that lymph node metastases are likely to be present in the subject. | 2009-03-12 |
20090068172 | Compositions and methods comprising binding proteins for adalimumab - Compositions and methods comprising proteins that bind specifically to adalimumab are disclosed herein. Adalimumab is a monoclonal antibody specific for the cytokine TNF-α and was developed to treat TNF-α mediated inflammatory diseases. In one aspect of the instant invention, the binding proteins are antibodies directed toward adalimumab. These antibodies, including binding fragments thereof, can be used in a clinical setting as well as for research and development. For example, these anti-adalimumab antibodies can be employed to neutralize adalimumab. | 2009-03-12 |
20090068173 | NOVEL CC-CHEMOKINE ANTAGONISTS - A novel CC-chemokine binding protein is isolated from the saliva of | 2009-03-12 |
20090068174 | THERAPEUTIC ALKALINE PROTEASE COMPOSITIONS AND USE IN FACILITATING THE TRANSPORT OF AGENTS ACROSS THE GASTROINTESTINAL MUCOSAL LINING - A method of treating an inflammatory condition involving TNF-α in a mammal by administering to a patient a composition with an effective amount of an isolated alkaline protease in an amount effective to inactive TNF-α. The invention also involves compositions, including pharmaceutical compositions containing an isolated alkaline protease in an amount effective to inactive TNF-α especially those from | 2009-03-12 |
20090068175 | Optimized FC Variants and Methods for Their Generation - The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants. | 2009-03-12 |
20090068176 | HUMAN NEUTRALIZING ANTIBODIES AGANST HEMOLYTIC UREMIC SYNDROME - Human and humanized monoclonal antibodies which binds specifically to subunit A of Shiga like toxin II have been developed which are effective to prevent or ameliorate one or more symptoms of HUS in a human. Effective dosages for treatment or prevention range from approximately 0.1 to 5.0 mg of antibody/kg of patient weight. The examples demonstrate the preferred dosage ranges based on the pig model, and what is being tested in phase I clinical trials. Antibodies are preferably transfused over a period of two hours, although this will depend on the patient and the disease state at the time of treatment. Preferred dosages for treatment of humans are between 0.1 mg/kg-5.0 mg/kg of 5C120, or an equivalent dosage of another antibody to subunit A of STX2. In the most preferred embodiments, dosages of 0.1 mg/kg, 0.5 mg/kg, or 5.0 mg/kg of 5C12 (low dose, anticipated therapeutic dose based on animal data and high dose) are administered. | 2009-03-12 |
20090068177 | Optimized Fc variants and methods for their generation - The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants. | 2009-03-12 |
20090068178 | Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin - The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same. | 2009-03-12 |
20090068179 | Methods for Inhibiting Carcinogenesis and/or Metastasis in an Individual with Endogenous C-Met Ligands and Inhibitors - Methods for inhibiting carcinogenesis and/or metastasis in an individual comprise administering to the individual an effective amount of endogenous c-met ligand or fragment thereof such as endogenous anti c-met immunoglobulin, native and/or recombinant; endogenous biological active Hepatocyte Growth Factor (HGF), native and/or recombinant, and/or a combination thereof. | 2009-03-12 |
20090068180 | COMPOSITIONS AND METHODS FOR TREATING IMMUNOLOGICAL AND INFLAMMATORY DISEASES AND DISORDERS - Methods and compositions for treating immunological and inflammatory diseases and disorders are disclosed. Particular methods and compositions comprise the administration of an agent that inhibits S1P lyase activity and at least one additional immunosuppressive and/or anti-inflammatory agent. | 2009-03-12 |
20090068181 | BISPECIFIC ANTIBODIES - The present invention provides compositions and methods for targeting stem cells to injured cardiac tissue. | 2009-03-12 |
20090068182 | Cytotoxicity mediation of cells evidencing surface expression of CD9 - This invention relates to the staging, diagnosis and treatment of cancerous diseases (both primary tumors and tumor metastases), particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB/chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays, which utilize the CDMAB of the instant invention. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells. | 2009-03-12 |
20090068183 | METHOD OF TREATING CANCER AND/OR CELLULAR PROLIFERATIVE CONDITIONS AND AGENTS TARGETING HYALURONAN ANABOLISM USEFUL FOR SAME - The present invention is directed to compounds, agents, pharmaceutically active agents, medicaments, therapeutics, actives, drugs and the like which specifically target a portion of the HAS molecule which is accessible to the extracellular environment in a first form of a cell but which is not accessible to the extracellular environment in another form of or in a transformed cell form the same or related cell. In particular, the present invention provides compounds which target a portion of HAS which is accessible to the extracellular environment in malignant or inflammatory or proliferative cells but which portion is not accessible to the external environment in “normal” cells. A “normal” cell in this instance is a non-malignant, inflammatory or proliferative cell. | 2009-03-12 |
20090068184 | Engineered Antibody-Stress Protein Fusions - Provided are fusion polypeptides comprising an engineered antibody and a stress protein that bind to antigens with high affinity, are highly immunogenic, exhibit MHC class I priming and are able to be produced in non-mammalian cells, such as | 2009-03-12 |
20090068185 | Asthma associated factors as targets for treating atopic allergies including asthma and related disorders - A new gene in the calcium-activated chloride channel family has been discovered that is induced by IL-9, thereby providing a therapeutic target in IL-9 mediated development of atopic allergy, asthma-related disorders and cystic fibrosis. A method for the identification and use of small molecule inhibitors of this gene and its products to treat these disorders has also been discovered. The invention also includes a method for diagnosing susceptibility to, and assessing treatment of atopic allergy, asthma-related disorders by measuring the level of gene expression in biologic samples using antibody specific for this protein. | 2009-03-12 |
20090068186 | MAP3Ks as modifiers of the p53 pathway and methods of use - Human MAP3K genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of MAP3K are provided. | 2009-03-12 |
20090068187 | Novel 14275, 54420, 8797, 27439, 68730, 69112 and 52908 molecules and uses therefor - The invention provides isolated nucleic acids molecules, designated 14275, 54420, 8797, 27439, 68730, 69112 or 52908 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 14275, 54420, 8797, 27439, 68730, 69112 or 52908 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 14275, 54420, 8797, 27439, 68730, 69112 or 52908 gene has been introduced or disrupted. The invention still further provides isolated 14275, 54420, 8797, 27439, 68730, 69112 or 52908 proteins, fusion proteins, antigenic peptides and anti-14275, 54420, 8797, 27439, 68730, 69112 or 52908 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided. | 2009-03-12 |
20090068188 | C-C chemokine receptor 3 proteins - The present invention relates to methods of inhibiting a mammalian C-C chemokine receptor 3 protein (CCR3). The invention further relates to methods of treating an inflammatory disease or condition. Administration of a compound which inhibits or promotes CCR3 function to an individual in need of therapy provides a new approach to selective modulation of leukocyte function, which is useful in a variety of inflammatory and autoimmune diseases, or in the treatment of infections. As a major leukocyte chemokine receptor present in leukocytes such as eosinophils and lymphocytes, the receptor provides a key target for drug screening and design. | 2009-03-12 |